Not FDA-approved1Evidence: Limited human dataBrain, nerves and sleep

Epitalon1

Also called AEDG, Epithalon, Ala-Glu-Asp-Gly1

Key takeaway

Epitalon is a synthetic four-amino-acid peptide first made in 1999. Most pharmacological studies of it come from one research group in Russia, and most of the research FDA reviewed was in animals.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no approved product containing it in any of the countries it checked.1 Human data are limited to a few small reports. FDA found no studies of epitalon in people with insomnia, the use it evaluated, and no clinical data supporting its safety.1 FDA staff recommended against adding epitalon to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.1,5,6

Epitalon at a glance

What it isA synthetic peptide of four amino acids (Ala-Glu-Asp-Gly). FDA treats it as a different substance from epithalamin, a pineal-gland extract it was modeled on.1
FDA statusNot FDA-approved. FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, epitalon acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,5,6
Human evidenceA few small reports, including one 20-day randomized study that measured a melatonin breakdown product rather than sleep. FDA found no studies in people with insomnia.1
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is epitalon?

Epitalon is a synthetic peptide made of four amino acids: alanine, glutamic acid, aspartic acid and glycine. It is also called epithalon or AEDG. It was designed from the amino-acid content of epithalamin, an extract of cattle pineal glands, but FDA treats the two as different substances.1

Epitalon appears to have been first synthesized in 1999. It received a U.S. orphan-drug designation for retinitis pigmentosa in 2010, and that designation was withdrawn in 2016.1

FDA found epitalon promoted online by wellness clinics as an anti-aging product, but could not identify any pharmacy that compounds it, and no outsourcing facility had reported compounding it.1

How is epitalon thought to work?

Because the pineal gland helps regulate the sleep-wake cycle, researchers have proposed that epitalon could affect daily body rhythms. In older female monkeys, one study reported higher evening melatonin and lower evening cortisol after treatment.1

How epitalon would change melatonin levels is unknown. A laboratory study found it did not directly increase melatonin release from rat pineal glands, and FDA found no animal studies that measured sleep itself.1

FDA’s briefing notes reports that epitalon can activate telomerase and lengthen telomeres. FDA says this raises a concern that long-term exposure could carry a cancer risk, and that the available mouse studies were too limited to rule that out.1

What do human studies show?

FDA evaluated epitalon for insomnia and found no studies of it in people with insomnia.1

The main human study FDA reviewed was a small 2021 randomized, placebo-controlled study in women working night shifts. Its authors reported that a melatonin breakdown product rose with epitalon, but the study did not measure sleep, did not state whether it was blinded, and was short.1

FDA found no clinical studies assessing epitalon’s safety and no pharmacokinetic data in people. Its searches of FDA’s adverse-event databases through December 2025 found no reports.1

FDA concluded that there is a lack of evidence that epitalon works for insomnia and no clinical data to support its safety in people.1

What the evidence base contains

  • Small, short, or incompletely reported human study A 2021 randomized, placebo-controlled study in 40 women working night shifts that measured a melatonin breakdown product over 20 days. FDA notes it did not state whether it was blinded, did not measure sleep, and did not report safety data.1
  • Small, short, or incompletely reported human study A 2002 report in people with retinitis pigmentosa, an inherited eye disease, and a meeting abstract stating that epitalon had no side effects in elderly people without giving study details.1
  • Animal or laboratory research Studies in monkeys, rats and mice reporting changes in melatonin and cortisol levels and fewer spontaneous tumors in female mice. FDA found no animal studies that measured sleep.1

Evidence-strength label: Limited human data. How this label is assigned

Is epitalon FDA-approved?

No. FDA’s May 2026 evaluation states that epitalon, in either its free-base or acetate form, is not a component of any FDA-approved drug and that there is no United States Pharmacopeia monograph for it.1

Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.5

FDA staff evaluated both forms of epitalon for that list for insomnia and recommended against adding either. They cited poor chemical characterization, a possible risk of immune reactions, no clinical safety data, a lack of evidence of effectiveness, and existing FDA-approved insomnia treatments.1

FDA’s compounding safety-risk page, last updated April 22, 2026, lists epitalon among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.3

HHS’s policy document states that epitalon was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.3,6

FDA’s Pharmacy Compounding Advisory Committee discussed epitalon on July 24, 2026. HHS’s policy document states that the committee voted in favor of including it, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,2,6

On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.5,6

Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For epitalon, the policy covers only the acetate salt form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.6

HHS and FDA staff weigh the same record differently. HHS’s policy document says newer certificates from FDA-registered facilities supply the quality test results FDA staff found missing, that historical use is now documented, and that FDA staff’s safety concerns are based on how epitalon might act rather than on observed harm. FDA staff had concluded that no clinical data support its safety in people.1,6

The policy does not make epitalon an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.5,6

Timeline

  1. Epitalon appears to have been first synthesized, according to the literature FDA reviewed.1
  2. Epitalon receives a U.S. orphan-drug designation for retinitis pigmentosa. The designation was withdrawn on January 6, 2016.1
  3. Epitalon is placed in FDA’s Category 2 of nominated compounding substances that may present significant safety risks, according to HHS’s policy document.6
  4. A Federal Register notice announces the July advisory-committee meeting that will discuss epitalon and opens a public comment docket.4
  5. Epitalon leaves Category 2, according to HHS’s policy document. FDA’s compounding safety-risk page, as last updated that day, lists it among withdrawn nominations.3,6
  6. FDA staff date their evaluation recommending that epitalon not be added to the 503A bulks list.1
  7. FDA’s Pharmacy Compounding Advisory Committee discusses epitalon.2
  8. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists epitalon among six peptide substances used in compounding.5,6

What is still unknown?

Whether epitalon improves sleep or any other health outcome in people: FDA found no studies in people with insomnia or other conditions that measured clinical outcomes.1

Its safety in people, including with long-term use, and whether its reported effect on telomeres carries a cancer risk.1

What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that inconsistent naming is a safety risk.1

Whether FDA’s rulemaking will add epitalon to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,5,6

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Epitalon: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Epitalon are the records PeptideScanner has selected and published, not every registration or paper about Epitalon. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not an FDA-approved drug. FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists epitalon acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make epitalon an FDA-approved drug.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 1.

Review source snapshots checked September 15, 2026 · Integrity checked not available.

Two selected reports discuss the tetrapeptide epitalon/AEDG: a mixed animal-and-human retinal report and a human circadian-biomarker report. This is not a review of the distinct pineal extract epithalamin.↗↗

What the reviewed sources report

These reports describe retinal findings and changes in melatonin-related or gene-expression measurements. Their abstracts do not provide enough detail to establish a reliable treatment effect, long-term safety or an effect on human lifespan.↗↗

What remains unresolved?

  • Which translated or related reports describe the same participants?↗↗
  • Do controlled studies assess patient-important outcomes and adequately report adverse events?↗↗

Read study designs, results, limitations, and sources →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Epitalon?

Manually reviewed September 15, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

Two selected reports discuss the tetrapeptide epitalon/AEDG: a mixed animal-and-human retinal report and a human circadian-biomarker report. This is not a review of the distinct pineal extract epithalamin.12

Bottom line from this bounded source set

These reports describe retinal findings and changes in melatonin-related or gene-expression measurements. Their abstracts do not provide enough detail to establish a reliable treatment effect, long-term safety or an effect on human lifespan.12

Reviewed study record

Retinal degeneration: mixed preclinical and clinical report

Design

The publication describes experiments in rats and clinical observations in patients with degenerative retinal lesions.1

Population

The abstract does not state the number of patients or their allocation to a comparator.1

Outcomes reported

The authors reported a positive clinical effect in 90% of cases and retinal effects in rats.1

Limitations

The clinical endpoint, comparator, follow-up and adverse events are insufficiently described in the abstract. The reported percentage is not a controlled effect estimate, and animal findings cannot establish human benefit.1

Reviewed study record

Circadian biomarkers

Design

The report examines AEDG and melatonin-related and clock-gene measurements in people with altered melatonin production.2

Population

The abstract does not give a sufficiently detailed enrollment and allocation account.2

Outcomes reported

The authors reported changes in urinary melatonin metabolite levels and clock-gene expression.2

Limitations

Biomarker changes do not establish better sleep, reduced disease or longer lifespan. Full-text and related-report reconciliation are required to assess design, participant overlap and harms.2

Reviewed source set

  1. PubMed · 12195242Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. ↗PubMed PMID 12195242 · EFetch XML reviewed 2026-09-15 · payload SHA-256 a1b48c7514114c06c30f237d71c4b8590b24d07f9f23d71e45867435d1c550f3
    Crossref check unavailableThe reviewed PubMed payload did not include a DOI, so this source could not be matched to a Crossref work endpoint.
  2. PubMed · 33280326[AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging.]. ↗PubMed PMID 33280326 · EFetch XML reviewed 2026-09-15 · payload SHA-256 e757964c067acf4126dfd5ac4ffcbc241bb42a87e59a298018bece424346ca97
    Crossref check unavailableThe reviewed PubMed payload did not include a DOI, so this source could not be matched to a Crossref work endpoint.
Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 1

Melatonin measurements do not establish an insomnia benefit

FDA’s July 2026 briefing found no studies evaluating the nominated substances in patients with insomnia. Changes in melatonin or its metabolites were not accompanied by clinical outcomes establishing that proposed use. FDA PDF pp. 40 ↗

More findings and the sources behind them

Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.

Human exposure is different from an adequate safety study

The briefing describes a 20-person exposure report without safety data and an abstract making a safety claim without essential methods. FDA also notes that it could not evaluate one Russian-language full article in English. FDA PDF pp. 36, 37 ↗

No reported events is not proof of safety

FDA’s cited adverse-event searches retrieved no reports, but the briefing explains voluntary-reporting and information limits. It separately found insufficient clinical safety data, especially for the proposed subcutaneous route. FDA PDF pp. 36, 38 ↗

Preclinical findings leave unresolved questions

FDA considered the animal studies too limited in duration and design to characterize genotoxic or carcinogenic potential. Mechanistic concerns in the briefing are not proof that epitalon causes cancer in people. FDA PDF pp. 40 ↗

What remains to be checked

  • Check subsequent advisory records and any final FDA action separately from the staff briefing.
  • Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

  • FDA epitalon briefing for the July 2026 advisory meeting ↗

    Source dated 2026-07-23; retrieved 2026-09-19.

    • Melatonin measurements do not establish an insomnia benefit · PDF pp. 40 of 64
    • Human exposure is different from an adequate safety study · PDF pp. 36, 37 of 64
    • No reported events is not proof of safety · PDF pp. 36, 38 of 64
    • Preclinical findings leave unresolved questions · PDF pp. 40 of 64

    SHA-256: 0dbe9252cdea634f279f9a8166f45ce561c43fb07c6eff517a9d15593f95931f

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Primary human administration reports for the specified molecule; other peptides, preclinical experiments and secondary reviews are separate.

140 retrieved · 2 included · 0 excluded · 138 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"epitalon"[Title/Abstract] OR "epithalon"[Title/Abstract] OR "AEDG"[Title/Abstract]

  • Regulator and trial-registry searches and non-indexed reports require separate reconciliation.
  • Full-text appraisal, study-family linkage and citation follow-up remain open.

Showing 25 of 140 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 33280326 — include: Selected human report; abstract and record metadata reviewed. Study families: AEDG-2020-2021-circadian-reports-linkage-unresolved.
  2. PubMed 12195242 — include: Selected human report; abstract and record metadata reviewed. Study families: epitalon-2002-retinal-report.
  3. PubMed 42209466 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  4. PubMed 42021992 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  5. PubMed 41490200 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  6. PubMed 41240216 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  7. PubMed 41020860 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  8. PubMed 40908429 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  9. PubMed 40493162 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  10. PubMed 40141333 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  11. PubMed 39788414 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  12. PubMed 39518916 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  13. PubMed 38430634 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  14. PubMed 39742404 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  15. PubMed 36979488 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  16. PubMed 37042594 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  17. PubMed 35890947 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  18. PubMed 35413689 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  19. PubMed 35408963 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  20. PubMed 34502859 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  21. PubMed 34998008 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  22. PubMed 33993656 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  23. PubMed 32987757 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  24. PubMed 31808038 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  25. PubMed 31677028 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"EPITALON"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:13.599491+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["Epitalon", "AEDG", "Epithalon"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["Epitalon", "AEDG", "Epithalon"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary identity terms: ["Epitalon", "AEDG", "Epithalon"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Document appraisal and national European sources remain open.
        • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          ClinicalTrials.gov search

          ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

          0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

          Search terms, record decisions and remaining work

          "Epitalon" OR "AEDG" OR "Epithalon"

          Source retrievals and payload pins
          • Open the source endpoint ↗

            Retrieved 2026-09-15T11:25:17.622604+00:00 · HTTP 200 · SHA-256 b54968c05ff881a1ef7ce604b6a340248f8e2aee8637bef06da0f5693f520df8.

          • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
          • Other registries, unregistered studies and additional aliases remain outside this query.

          Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

            Explore status sources, recent additions, and coverage gaps

            Living status brief

            What is the current status of Epitalon?

            Not an FDA-approved drug. FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists epitalon acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make epitalon an FDA-approved drug.↗↗↗↗

            The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

            Evidence present

            What records are connected here?

            Evidence lanes
            2
            Source years
            6
            Drugs@FDA applications
            0

            These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

            Coverage gaps

            What remains unknown or unsupported?

            PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

            PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

            Explore the Evidence Map and record counts

            Evidence Map v1

            What kinds of records connect to Epitalon?

            Compare collection coverage →

            This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

            26Selected dated records
            36Connected citations
            6Populated source years2012–2026
            2/4Record lanes present

            Registered human studies

            Trial composition

            0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

            PubMed bibliography

            Publication composition

            1 of 24 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

            Publication typesJournal Article 1Review 1

            Bibliography fields unavailable here for 23 selected records; the records remain visible as metadata observations.

            Regulatory and publication surfaces

            What is structurally connected?

            Drugs@FDA applications
            0
            FDA Federal Register documents
            1
            DailyMed SPL versions
            0
            Canonical profile
            Published
            Profile structured data
            Published
            Linked dated records
            26

            Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

            Profile publication history and record counts
            Source records by collection · 26 dated records

            Research hub

            Explore the Epitalon evidence record

            Open all 26 records →
            26Dated records
            2Evidence types
            33Cited public sources
            6Source years

            Change ledger

            Recently changed for Epitalon

            Open all 28 events →

            PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

            Profile status changed

            Epitalon profile

            We added a plain-language reader guide with cited answers, re-checked FDA’s epitalon briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists epitalon acetate. FDA has not issued a final 503A rule.

            PeptideScanner change date
            November 14, 2026
            Evidence lane
            Profile
            Record added

            Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence.

            PubMed lists PMID 42884164 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-10-08 (day precision). PeptideScanner associated the retained record with the identity slug epitalon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

            PeptideScanner change date
            November 14, 2026
            Cited source date
            October 20, 2026
            Evidence lane
            Literature metadata

            Official-source collections

            Source records for Epitalon

            Open the full research atlas →

            Evidence types

            Coverage by source year

            Selected records span November 15, 2012 to October 20, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

            Continue exploring

            Profiles with overlapping source-year coverage

            Open the research atlas →

            These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

            Organizations and trial records named in cited sources

            Organizations named in cited records

            • U.S. Food and Drug Administration1,2
            • U.S. Department of Health and Human Services5
            Dated updates connected to this profile · 26

            Updates connected to this profile

            Open the full cross-source timeline →
            1. Literature metadata

              Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence.↗

              PubMed lists PMID 42884164 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-10-08 (day precision). PeptideScanner associated the retained record with the identity slug epitalon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

            2. Regulatory

              FDA committee met on seven peptide-related groups of bulk drug substances↗

              FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗

            3. Literature metadata

              PubMed record PMID 40493162↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 40493162 at 2026-07-30T16:14:11.014Z. PubMed recorded a metadata revision date of 2026-06-13 and an Entrez history date of 2025-06-10. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗

            4. Literature metadata

              PubMed record PMID 41240216↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 41240216 at 2026-07-30T16:20:41.667Z. PubMed recorded a metadata revision date of 2026-05-20 and an Entrez history date of 2025-11-15. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗

            5. Regulatory

              Federal Register notice 2026-07361↗

              The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.↗

            6. Literature metadata

              PubMed record PMID 12209581↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 12209581 at 2026-07-30T16:30:44.156Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2002-09-05. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗

            7. Literature metadata

              PubMed record PMID 25535022↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 25535022 at 2026-07-30T20:43:08.960Z. PubMed recorded a metadata revision date of 2019-12-10 and an Entrez history date of 2014-12-24. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗

            8. Literature metadata

              PubMed record PMID 14501183↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 14501183 at 2026-07-30T20:44:18.228Z. PubMed recorded a metadata revision date of 2019-11-08 and an Entrez history date of 2003-09-23. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗

            9. Literature metadata

              PubMed record PMID 11087911↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 11087911 at 2026-07-30T20:48:24.194Z. PubMed recorded a metadata revision date of 2019-08-31 and an Entrez history date of 2000-11-23. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗

            10. Literature metadata

              PubMed record PMID 12049808↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 12049808 at 2026-07-30T20:50:08.377Z. PubMed recorded a metadata revision date of 2019-07-20 and an Entrez history date of 2002-06-07. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗

            11. Literature metadata

              PubMed record PMID 12101568↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 12101568 at 2026-07-30T21:22:56.967Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2002-07-10. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗

            12. Literature metadata

              PubMed record PMID 15490730↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 15490730 at 2026-07-30T21:35:53.278Z. PubMed recorded a metadata revision date of 2016-10-21 and an Entrez history date of 2004-10-20. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗

            Citations

            Sources

            Coverage and sources →

            Numbered markers in the text point here. Each link opens the original public record.

            1. 1
              FDA briefing document for epitalon ↗

              U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

            2. 2
              July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

              U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

            3. 3
              Certain bulk drug substances for use in compounding that may present significant safety risks ↗

              U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

            4. 4
              Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

              Federal Register via GovInfo · Official source · Source checked August 21, 2026

            5. 5
              Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

              Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

            6. 6
              HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

              U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026